Table I.
Median plasma concentrations (interquartile range) of ADMA and IIEF score grouped according to categorical baseline variables
| N | ADMA [µmol/l] | P value | N | IIEF (score) | P value | |
|---|---|---|---|---|---|---|
| Risk factors | ||||||
| Hypertension | ||||||
| Yes | 21 | 0.44 (0.06–1.30) | 26 | 18 (1–30) | ||
| No | 36 | 0.55 (0.09–1.41) | 0.155 | 44 | 20 (1–30) | 0.363 |
| Diabetes mellitus | ||||||
| Yes | 9 | 0.16 (0.06–0.84) | 15 | 11 (1–26) | ||
| No | 48 | 0.54 (0.09–1.41) | 0.001 | 53 | 21 (1–30) | 0.002 |
| Hyperlipidaemia | ||||||
| Yes | 6 | 0.34 (0.08–0.71) | 7 | 26 (15–30) | ||
| No | 51 | 0.50 (0.06–1.41) | 0.233 | 63 | 19 (1–30) | 0.116 |
| Smoking current | ||||||
| Yes | 33 | 0.55 (0.09–1.41) | 41 | 20 (1–30) | ||
| No | 24 | 0.45 (0.06–1.28) | 0.070 | 29 | 15 (1–30) | 0.031 |
| Smoking former | ||||||
| Yes | 46 | 0.50 (0.08–1.41) | 57 | 19 (1–30) | ||
| No | 11 | 0.47 (0.06–1.28) | 0.537 | 13 | 20 (1–30) | 0.867 |
| Medication | ||||||
| β-Blocker therapy | ||||||
| Yes | 14 | 0.52 (0.08–1.13) | 16 | 24 (1–30) | ||
| No | 43 | 0.47 (0.06–1.41) | 0.882 | 54 | 18.5 (1–30) | 0.187 |
| ACE inhibitors therapy | ||||||
| Yes | 15 | 0.49 (0.06–1.30) | 17 | 21 (1–30) | ||
| No | 42 | 0.52 (0.08–1.41) | 0.906 | 53 | 19 (1–30) | 0.283 |
| AT2 receptor blocker therapy | ||||||
| Yes | 5 | 0.43 (0.08–0.97) | 7 | 22 (1–30) | ||
| No | 52 | 0.52 (0.06–1.41) | 0.401 | 63 | 19 (1–30) | 0.549 |
| Calcium antagonist therapy | ||||||
| Yes | 4 | 0.78 (0.38–1.13) | 4 | 15.5 (1–28) | ||
| No | 53 | 0.49 (0.06–1.41) | 0.142 | 66 | 19.5 (1–30) | 0.470 |
| Diuretic therapy | ||||||
| Yes | 1 | 1.30 (1.30–1.30) | 1 | 30 (30–30) | ||
| No | 56 | 0.49 (0.06–1.41) | 0.070 | 69 | 19 (1–30) | 0.143 |
| Statin therapy | ||||||
| Yes | 5 | 0.58 (0.28–1.13) | 7 | 26 (9–30) | ||
| No | 52 | 0.49 (0.06–1.41) | 0.671 | 63 | 19 (1–30) | 0.242 |
| Acetylsalicylic acid therapy | ||||||
| Yes | 18 | 0.46 (0.06–1.41) | 20 | 21.5 (1–30) | ||
| No | 39 | 0.54 (0.12–1.28) | 0.589 | 50 | 19 (1–30) | 0.293 |
| Clopidogrel therapy | ||||||
| Yes | 5 | 0.50 (0.28–1.13) | 6 | 20.5 (1–30) | ||
| No | 52 | 0.49 (0.06–1.41) | 0.838 | 64 | 19 (1–30) | 0.976 |
| Anticoagulant therapy | ||||||
| Yes | 1 | 0.49 (0.49–0.49) | 1 | 24 (24–24) | ||
| No | 56 | 0.50 (0.06–1.41) | 0.982 | 69 | 19 (1–30) | 0.686 |
| Oral antidiabetic therapy | ||||||
| Yes | 6 | 0.06 (0.08–0.84) | 9 | 12 (1–26) | ||
| No | 51 | 0.54 (0.06–1.41) | 0.017 | 61 | 20 (1–30) | 0.032 |
| Insulin therapy | ||||||
| Yes | 3 | 0.15 (0.06–0.84) | 3 | 1 (1–18) | ||
| No | 54 | 0.50 (0.08–1.41) | 0.259 | 67 | 20 (1–30) | 0.058 |
| Coronary vessels involvement | ||||||
| One-vessel disease | ||||||
| Yes | 17 | 0.54 (0.16–1.28) | 21 | 24 (1–30) | ||
| No | 40 | 0.47 (0.06–1.41) | 0.958 | 49 | 18 (1–30) | 0.053 |
| Two-vessel disease | ||||||
| Yes | 18 | 0.61 (0.18–1.26) | 20 | 18.5 (1–30) | ||
| No | 39 | 0.47 (0.06–1.41) | 0.066 | 50 | 20 (1–30) | 0.527 |
| Three-vessel disease | ||||||
| Yes | 22 | 0.35 (0.06–1.41) | 29 | 18 (1–30) | ||
| No | 35 | 0.55 (0.16–1.28) | 0.071 | 41 | 20 (1–30) | 0.222 |
| Total occlusion | ||||||
| Yes | 13 | 0.38 (0.06–1.10) | 15 | 18 (1–30) | ||
| No | 44 | 0.54 (0.09–1.41) | 0.068 | 55 | 20 (1–30) | 0.499 |
| Revascularisation | ||||||
| Yes | 36 | 0.43 (0.06–1.30) | 45 | 21 (1–30) | ||
| No | 21 | 0.54 (0.16–1.41) | 0.317 | 25 | 15 (1–30) | 0.056 |